BIRC5 and cancer: For example, the AURKA inhibitor MLN8237, the BIRC5 inhibitor YM155 and the MELK kinase inhibitor OTS167 have been tested in clinical trials for different types of cancers, and a TTK kinase inhibitor has also shown anti-cancer activity [57].